Literature DB >> 6376518

Improved acceptance of frozen bone allografts in genetically mismatched dogs by immunosuppression.

V M Goldberg, G D Bos, K G Heiple, J M Zika, A E Powell.   

Abstract

UNLABELLED: We studied the role of immunosuppressive therapy in improving the incorporation of frozen bone allografts exchanged across strong transplantation barriers in a canine cancellous ulnar segmental replacement model. Dogs receiving frozen bone from donors with major histocompatibility differences received one of three different immunosuppressive treatments. In two groups, azathioprine and prednisolone were administered for either twenty-eight or fifty-six days; anti-lymphocyte globulin was added for another twenty-eight-day group in a third regimen. Frozen bone was evaluated radiographically and histologically by criteria that quantified the biological characteristics of the bone itself and union between the graft and host at thirteen and twenty-six weeks after grafting. Graft incorporation in these animals was compared with graft acceptance in a similar group of untreated animals and in untreated animals in which bone was exchanged across weak transplantation barriers. Complications of immunosuppression included wound drainage, infection, weight loss, and falling white-blood-cell counts. Seven of the original thirty-seven animals died as a direct result of these complications. After twenty-six weeks the grafts in the recipients receiving immunosuppression appeared radiographically and histologically indistinguishable from those in the untreated, genetically closely matched group and from autografts. They were significantly better incorporated than identical allografts placed in untreated, genetically disparate recipients. There was no difference in the effectiveness of any of the immunosuppressive programs. CLINICAL RELEVANCE: Immunosuppression improves the biological outcome of otherwise poorly performing frozen bone allografts in dogs. This finding suggests that treatments that modify the immunological response of the host without major side effects may be useful clinically in improving the success of massive frozen bone allografts.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376518     DOI: 10.2106/00004623-198466060-00016

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  6 in total

Review 1.  [Osteoinduction and -reparation].

Authors:  N R Kübler
Journal:  Mund Kiefer Gesichtschir       Date:  1997-02

2.  Segmental bone grafting. Comparison of different types of graft in dogs.

Authors:  M Aebi; P Regazzoni; O Schwarzenbach
Journal:  Int Orthop       Date:  1989       Impact factor: 3.075

3.  [Use of allografts in oncology and traumatology].

Authors:  D Poitout; G Novakovitch
Journal:  Int Orthop       Date:  1987       Impact factor: 3.075

4.  Increased bone ingrowth distance into lipid-extracted bank bone at 6 weeks. A titanium chamber study in allogeneic and syngeneic rats.

Authors:  K Thorén; P Aspenberg
Journal:  Arch Orthop Trauma Surg       Date:  1995       Impact factor: 3.067

5.  Immune inhibition of repair of canine skull trephine defects implanted with partially purified bovine morphogenetic protein.

Authors:  O S Nilsson; M R Urist
Journal:  Int Orthop       Date:  1991       Impact factor: 3.075

6.  GluN2A-selective positive allosteric modulator-nalmefene-flumazenil reverses ketamine-fentanyl-dexmedetomidine-induced anesthesia and analgesia in rats.

Authors:  Chunzhu Li; Jia Yan; Dewei Tang; Jidong Zhu; Chen Huang; Yu Sun; Rong Hu; Hao Wang; Chaoying Fu; Yelin Chen; Hong Jiang
Journal:  Sci Rep       Date:  2020-03-24       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.